TY - JOUR
T1 - Clinical practice guideline for the medical management of perianal fistulizing Crohn's disease
T2 - The Toronto consensus
AU - Steinhart, A. Hillary
AU - Panaccione, Remo
AU - Targownik, Laura
AU - Bressler, Brian
AU - Khanna, Reena
AU - Marshall, John K.
AU - Afif, Waqqas
AU - Bernstein, Charles N.
AU - Bitton, Alain
AU - Borgaonkar, Mark
AU - Chauhan, Usha
AU - Halloran, Brendan
AU - Jones, Jennifer
AU - Kennedy, Erin
AU - Leontiadis, Grigorios I.
AU - Loftus, Edward V.
AU - Meddings, Jonathan
AU - Moayyedi, Paul
AU - Murthy, Sanjay
AU - Plamondon, Sophie
AU - Rosenfeld, Greg
AU - Schwartz, David
AU - Seow, Cynthia H.
AU - Williams, Chadwick
N1 - Publisher Copyright:
© 2018 Crohn's and Colitis Foundation. Published by Oxford University Press. All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background Fistulas occur in about 25% of patients with Crohn's disease (CD) and can be difficult to treat. The aim of this consensus was to provide guidance for the management of patients with perianal fistulizing CD. Methods A systematic literature search identified studies on the management of fistulizing CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform using a modified Delphi process, then finalized, and voted on by a group of specialists. Results The quality of evidence for treatment of fistulizing CD was generally of very low quality, and because of the scarcity of good randomized controlled trials (RCTs), these consensus statements generally provide conditional suggestions (5 of 7 statements). Imaging and surgical consultations were recommended in the initial assessment of patients with active fistulizing CD, particularly those with complicated disease. Antibiotic therapy is useful for initial symptom control. Antitumor necrosis factor (anti-TNF) therapy was recommended to induce symptomatic response, and continued use was suggested to achieve and maintain complete remission. The use of concomitant immunosuppressant therapies may be useful to optimize pharmacokinetic parameters when initiating anti-TNF therapy. When there has been an inadequate symptomatic response to medical management strategies, surgical therapy may provide effective fistula healing for some patients. Conclusions Optimal management of perianal fistulizing CD requires a collaborative effort between gastroenterologists and surgeons and may include the evidence-based use of existing therapies, as well as surgical assessments and interventions when needed.
AB - Background Fistulas occur in about 25% of patients with Crohn's disease (CD) and can be difficult to treat. The aim of this consensus was to provide guidance for the management of patients with perianal fistulizing CD. Methods A systematic literature search identified studies on the management of fistulizing CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform using a modified Delphi process, then finalized, and voted on by a group of specialists. Results The quality of evidence for treatment of fistulizing CD was generally of very low quality, and because of the scarcity of good randomized controlled trials (RCTs), these consensus statements generally provide conditional suggestions (5 of 7 statements). Imaging and surgical consultations were recommended in the initial assessment of patients with active fistulizing CD, particularly those with complicated disease. Antibiotic therapy is useful for initial symptom control. Antitumor necrosis factor (anti-TNF) therapy was recommended to induce symptomatic response, and continued use was suggested to achieve and maintain complete remission. The use of concomitant immunosuppressant therapies may be useful to optimize pharmacokinetic parameters when initiating anti-TNF therapy. When there has been an inadequate symptomatic response to medical management strategies, surgical therapy may provide effective fistula healing for some patients. Conclusions Optimal management of perianal fistulizing CD requires a collaborative effort between gastroenterologists and surgeons and may include the evidence-based use of existing therapies, as well as surgical assessments and interventions when needed.
KW - antibiotic
KW - antitumor necrosis factor
KW - endoscopic ultrasound
KW - magnetic resonance imaging
KW - recommendations
UR - http://www.scopus.com/inward/record.url?scp=85058611505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058611505&partnerID=8YFLogxK
U2 - 10.1093/ibd/izy247
DO - 10.1093/ibd/izy247
M3 - Review article
C2 - 30099529
AN - SCOPUS:85058611505
SN - 1078-0998
VL - 25
SP - 1
EP - 13
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 1
ER -